

References - Case Study #14 Secondary Hyperlipidemia

- Busby-Whitehead, & Blackman, Marc. (1999). Clinical implications of abnormal lipoprotein metabolism. In Barker, L.R.(Ed). Ambulatory medicine. Baltimore: Williams and Wilkins.
- Chipkin, S. (1996). Lipid disorders. In Noble, John (Ed). Textbook of primary care medicine. Mosby: St. Louis.
- Lind, L., Lithell, H. (1993). Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. American Heart Journal. 125(5 Pt 2):1494-7.
- Malloy, Mary, & Kane, John. (1998). Agents used in hyperlipidemia. In Katzung, Bertram (Ed). Basic and clinical pharmacology. (pp563-577). Appleton&Lange: Stanford, CT.
- McBride, P. & Underbakke, G. (1994). Dyslipidemias. In David, Alan (Ed). Family medicine: Principles and practice. (pp956-963). Springer-Verlag: NY.
- National Cholesterol Education Program. Second report of the expert panel of detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994;89:1333-445.
- Parker, J., Ferrell, B. Lahey, K. (1987). Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. New england journal of medicine. 89:1333-445.
- Spencer, A, Carson, D, Crouch, M. (1999). Vitamin e and coronary artery disease. Archives of internal medicine. Vol 159;1313-1320.
- Scandinavian simvastatin survival study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Uphold, C., & Graham, M. (1998). Dyslipidemia. In Clinical guidelines in family practice (3rd ed). Barmaerae Books: Gainesville, FL.
- Wells, R. & DiPiro, J. (1998). Pharmacotherapy Handbook(7th ed). Appleton & Lange: Stamford: CT.